# A Study of BGM-2121 in Patients With Advanced Solid Tumors

> **NCT07346846** · PHASE1 · RECRUITING · sponsor: **BioGate Precision Medicine Corp.** · enrollment: 35 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** BGM-2121

## Key facts

- **NCT ID:** NCT07346846
- **Lead sponsor:** BioGate Precision Medicine Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2027-11
- **Final completion:** 2028-12
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07346846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07346846, "A Study of BGM-2121 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07346846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*